BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
DENVER, April 25, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million...
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by...
Kathy Schilling, MD, Boca Raton Regional Hospital, to discuss how ProFound AI helped nine dedicated breast radiologists find 23% more...
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions at 60 Seconds Results to...
First-ever orphan drug designation for genetically modified gamma-delta T cell therapiesThis orphan drug designation offers potential 7-year market exclusivity for...
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical researchRESEARCH TRIANGLE PARK, N.C., April...
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology...
Carlsbad, California, April 25, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a...
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical...
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post...
Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications Building innovative internal pipeline in oncology TORONTO, April 25,...
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the...
Three U.S. clinical trial sites actively screening and enrolling patientsTop line data of adrulipase in Cystic Fibrosis patients expected in...
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a...